title: Investigation of Gastroduodenal Mucosal Injury in Japanese Asymptomatic Antiplatelet Drug Users.
abstract: Antiplatelet drugs are widely used for the prevention of cardiovascular disease and cerebral vascular disorders. Although there have been several studies on gastroduodenal mucosal injury with gastrointestinal (GI) symptoms such as GI bleeding, in antiplatelet drug users (including low-dose aspirin (LDA)), there have been few reports on the association between antiplatelet drug use and gastroduodenal mucosal injury in asymptomatic antiplatelet drug users. This study was a cross-sectional study elucidating the association between antiplatelet drug use and gastroduodenal mucosal injury in asymptomatic antiplatelet drug users.Subjects were 186 asymptomatic Japanese antiplatelet drug users who underwent a regular health checkup. Subjects were divided into those with and without gastroduodenal mucosal injury endoscopically, and the association between gastroduodenal mucosal injury and other data in asymptomatic antiplatelet drug users was investigated.The prevalence of males and drinkers were significantly higher in subjects with gastroduodenal mucosal injury than in those without. In addition, the prevalence of proton pump inhibitor (PPI) users was significantly lower in subjects with gastroduodenal mucosal injury than in subjects without gastroduodenal mucosal injury. Logistic regression analysis showed PPI (odds ratios: 0.116; 95% confidence intervals: 0.021-0.638; P < 0.05) was a significant predictor of a decreased prevalence of gastroduodenal mucosal injury and closed-type (C-type) atrophy (3.172; 1.322-7.609; P < 0.01) was a significant predictor of an increased prevalence of severe gastroduodenal mucosal injury in asymptomatic antiplatelet drug users.Gender and lifestyle, such as drinking, may have an impact on risk of gastroduodenal mucosal injury in asymptomatic subjects taking antiplatelet drugs. Although PPI is a significant predictor of a decreased prevalence of gastroduodenal mucosal injury, including in asymptomatic antiplatelet drug users, status of gastric atrophy should also be considered against severe gastroduodenal mucosal injury.
authors.affiliation: From the Department of General Medicine and Community Health Science, Institute of Health, Biosciences, Tokushima University Graduate School (MS, TO); Department of Gastroenterology and Oncology, Institute of Health Biosciences, Tokushima University Graduate School, Tokushima (MS, TO, YF, YM, YT, TK, KO, NM, TT); Department of Gastroenterology, Kagawa Prefectural Cancer Detection Center, Takamatsu, Japan (MS); Department of Internal Medicine, Tsurugi Municipal Handa Hospital, Tokushima, Japan (MN).
authors.forename: Masahiro
authors.initials: M
authors.lastname: Sogabe
authors.forename: Toshiya
authors.initials: T
authors.lastname: Okahisa
authors.forename: Masahiko
authors.initials: M
authors.lastname: Nakasono
authors.forename: Yasuteru
authors.initials: Y
authors.lastname: Fujino
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Mitsui
authors.forename: Yoshihumi
authors.initials: Y
authors.lastname: Takaoka
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Kimura
authors.forename: Koichi
authors.initials: K
authors.lastname: Okamoto
authors.forename: Naoki
authors.initials: N
authors.lastname: Muguruma
authors.forename: Tetsuji
authors.initials: T
authors.lastname: Takayama
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016099:Endoscopy, Gastrointestinal; D005260:Female; D005753:Gastric Mucosa / Q000293:injuries*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D012189:Retrospective Studies; D013272:Stomach Diseases / Q000139:chemically induced* / Q000175:diagnosis; D055815:Young Adult
chemical_list: D010975:Platelet Aggregation Inhibitors